✦ LIBER ✦

Phase II trial of thalidomide with chemotherapy and as maintenance therapy for patients with poor prognosis small-cell lung cancer

✍ Scribed by Lee, Siow Ming; James, Lindsay; Buchler, Tomas; Snee, Mike; Ellis, Paul; Hackshaw, Allan

Book ID: 119319758
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 151 KB
Volume: 59
Category: Article
ISSN: 0169-5002
DOI: 10.1016/j.lungcan.2007.08.032

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II trial of thalidomide as mainten

Phase II trial of thalidomide as maintenance therapy for extensive stage small cell lung cancer after response to chemotherapy

✍ Dowlati, Afshin; Subbiah, Shanmuga; Cooney, Matthew; Rutherford, Kimberly; Mekha 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 174 KB

Phase II trial of Sorafenib in conjuncti

Phase II trial of Sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer

✍ Sharma, Neelesh; Pennell, Nathan; Nickolich, Myles; Halmos, Balazs; Ma, Patrick; 📂 Article 📅 2014 🏛 Springer US 🌐 English ⚖ 194 KB

Phase II Trial: Concurrent Chemotherapy

Phase II Trial: Concurrent Chemotherapy and Radiation Therapy With Nitroglycerin in Locally Advanced Non-small Cell Lung Cancer Patients

✍ Blake, M.; De La Mata, D.; Zamora, J.; Peña, O.; Macedo, O.; Flores Estrada, D.; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 56 KB

Vindesine and etoposide chemotherapy in

Vindesine and etoposide chemotherapy in the management of patients with small cell lung cancer and poor prognosis

📂 Article 📅 1991 🏛 Elsevier Science 🌐 English ⚖ 293 KB

Phase II trial of vindesine and VP16-213

Phase II trial of vindesine and VP16-213 in the palliation of poor-prognosis patients and elderly patients with small cell lung cancer

✍ Simon G. Allan; Anna Gregor; Michael A. Cornbleet; Robert C. F. Leonard; John F. 📂 Article 📅 1984 🏛 Springer 🌐 English ⚖ 320 KB

Forty-three previously untreated patients, all of whom had poor-prognosis small cell lung cancer and/or were greater than 65 years old, received treatment with vindesine and VP16-213. Thirteen patients had limited disease and 30 extensive disease. Response rates (CR + PR) of 86% (CR 29%) and 66% (CR

A phase II trial of gefitinib as mainten

A phase II trial of gefitinib as maintenance therapy after first-line chemotherapy for advanced non-small cell lung cancer in China

✍ Lu Yang; Zhi-jie Wang; Tong-tong An; Hua Bai; Jun Zhao; Jian-chun Duan; Ping-pin 📂 Article 📅 2010 🏛 Chinese Anti-Cancer Association 🌐 English ⚖ 283 KB